Alterity Therapeutics Ltd. · ASX:ATH
Alterity Therapeutics — Shareholder Meeting (November 2025)
24 slides from Alterity Therapeutics's shareholder meeting presentation, Nov 21, 2025
Slide 1: CEO's presentation
CEO’s presentation Dr David Stamler 21 November 2025
Slide 2: Forward looking statements
Forward looking statements 2 This presentation may contain some statements that may be considered “Forward - Looking Statements”, within the meaning of the US Securities Laws. Thus, any forward - looking statement relating to financial projections or other statements relating to the Company’s plans,
Slide 3: Investment highlights
Investment highlights 3 Large market potential in neurodegenerative diseases Highly experienced leadership team in movement disorders Oral administration preferred over competition Positive Phase 2 data in Multiple system atrophy (MSA), an aggressive Parkinsonian disorder Robust efficacy on function
Slide 4: Promising portfolio in neurodegenerative diseases
Promising portfolio in neurodegenerative diseases 4 Program: Drug discovery Indication: Discovery Pre - clinical Phase 1 Natural History Positive topline data Positive topline data Phase 2 Phase 3 Collaboration Multiple system atrophy Open label study Parkinson’s disease Neurodegenerative diseases F
Slide 5: Multiple System Atrophy (MSA): Parkinsonian disorder with no approved treatment
Multiple System Atrophy (MSA): Parkinsonian disorder with no approved treatment 0 Years: 3 6 9 7.5 years median survival after symptom onset Over 50% require wheelchair in 5 years Rapidly progressive Highly debilitating Up to 50,000 patients in U.S. Disease characteristics: • Motor: Parkinsonism, un
Slide 6: ATH434: Small molecule drug candidate
ATH434: Small molecule drug candidate 6 Broad treatment potential Potential to treat many neurodegenerative diseases (e.g., Parkinson’s, Frederich Ataxia) Orphan & Fast Track designations US FDA Fast Track Designation and Orphan drug designation in U.S. and EU Blood - brain barrier penetrant Acts in
Slide 7: Targeting the pathology of MSA
Targeting the pathology of MSA
Slide 8: Key players in MSA pathology
8 Key players in MSA pathology Two forms of iron required for cellular function: • Energy production and activity of many enzymes • Neurotransmitter synthesis (e.g., dopamine) • Myelin synthesis α - Synuclein protein: • Present in all neurons • Regulates neurotransmitter release • Facilitates neuron
Slide 9: ATH434 mechanism of action: Iron chaperone
Fe 3+ Stable Fe 3+ Fe 2+ Reactive Fe 2+ ATH434 mechanism of action: Iron chaperone ATH434 redistributes excess labile (reactive) iron to reduce neuronal injury Sources: Adapted from Yanatori et al., BBA 2020 and Philpott et al., Frontiers Mol Bio. 2023 | Pall, et al. Metallomics, 2024. Buffering Fe
Slide 10: Treatment approach: Address underlying pathology
Treatment approach: Address underlying pathology 10 Based on its mechanism of action, ATH434 is a potential disease modifying therapy ATH434 redistributes excess labile iron in the CNS Reduces α - synuclein aggregation and oxidative injury Preserves neurons and oligodendrocyte support cells Stabilis
Slide 11: ATH434 clinical development program in MSA
ATH434 clinical development program in MSA
Slide 12: Diligent approach to de-risk development program
Diligent approach to de - risk development program 12 • Observational study in individuals with MSA • Designed to de - risk clinical development program • Identify biomarkers to improve accuracy of patient selection Phase 2 ATH434 - 201 ATH434 - 202 Randomized double - blind placebo - controlled tri
Slide 13: Phase 2 randomized, double-blind, placebo-controlled study design
ATH434 - 201: Randomized, double - blind, placebo - controlled study 13 N=77 Study design: Endpoints: Patient criteria: • Clinical diagnosis of MSA • Motor symptoms ≤4 years • No severe impairment • Elevated brain iron on MRI • Elevated plasma NfL Placebo twice daily 50 mg twice daily Key clinical e
Slide 14: Importance of the Unified MSA Rating Scale Part I (UMSARS I)
Importance of the U nified MSA R ating S cale Part I (UMSARS I) 14 ATH434 - 201 Speech Walking Swallowing Falling Handwriting Orthostatic symptoms Cutting food Urinary function Dressing Bowel function Hygiene Sexual function ^ Validated rating scale to assess MSA disease severity Rates functional im
Slide 15: Clinically significant efficacy on modified UMSARS Part I
Clinically significant efficacy on modified UMSARS Part I Change from baseline to week 52 15 ATH434 - 201 worsening Modified UMSARS I Relative treatment effect Difference vs. placebo LS mean (SE ) Placebo N=22 48% - 3.8 (1.6) ATH434 50 mg N=25 30% - 2.4 (1.7) ATH434 75 mg N=24 Change Placebo Relativ
Slide 16: Orthostatic Hypotension Symptom Assessment (OHSA)
Orthostatic Hypotension Symptom Assessment (OHSA) Change from baseline to week 52 10 5 - 5 0 Change In OHSA (week S2 BL) • Assesses symptoms of low blood pressure when going from sitting to standing (e.g., dizziness / feeling faint / lightheadedness) • Patient reported outcome p=0.08 worsening mean
Slide 17: ATH434 preserved walking in outpatient setting
0 - 50 - 100 worsening 17 ATH434 - 201 Step count worsening 0 - 1000 - 2000 - 3000 Change In steps/day p = 0.04 * p = 0.10 Total time walking Change In bouts/day Total standing time Pendant Wearable movement sensor ATH434 - 201 50 mg ATH434 - 201 75 mg Placebo Change In minutes/day 0 - 10 - 20 - 40
Slide 18: Adverse Events
18 1 - Reporting one or more event 2 - None related to Study Drug ATH434 - 201 • Similar rates of AEs in ATH434 and placebo participants • No severe or serious AEs related to study drug • No hematologic side effects ATH434 - 201 ATH434 - 201 Placebo 75 mg N=26 50 mg N=25 twice daily subjects 1 N=26
Slide 19: ATH434-202: Open label study in advanced MSA
ATH434 - 202: Open label study in advanced MSA 19 Key objective was to assess efficacy and safety of ATH434 75 mg dose for comparison to 75 mg dose in 201 double - blind study ATH434 - 201 75mg BID N=24 ATH434 - 202 75 mg BID N=10 Parameter 63.9 (6.7) 64.5 (7.5) Age (yr) 2.3 (0.9) 3.9 (1.8) Duration
Slide 20: ATH434-202: Key data at 75 mg dose
ATH434 - 201 75mg BID N=24 ATH434 - 202 75 mg BID N=10 Change over 12 Months 5.6 (5.6) 3.5 (4.7) Modified UMSARS I 21% 30% Clinical global impression of change (% stable) 26.4% 30% Patient global impression of change (% stable) - 0.42 (0.29) - 0.44 (0.14) Brain volume 1 Mean (SD) ATH434 - 202: Key d
Slide 21: Approach to commercial assessment
Approach to commercial assessment Conducted by independent marketing research and forecasting group 21 • Conduct secondary market research Assess unmet needs and competitive landscape • Develop target product profile based on Phase 2 clinical data • Qualitative research Conduct In - depth interviews
Slide 22: Commercial opportunity in MSA
Commercial opportunity in MSA Key attributes of ATH434 drive significant value 22 USD $2.4 Billion Potential worldwide annual peak sales for ATH434 in MSA Severely debilitating illness with no approved treatment ripe for new entrants Critical need for a tolerable, disease modifying therapy Importanc
Slide 23: 2025: Strengthening the Foundation for the Future
1 2 3 4 2025: Strengthening the Foundation for the Future 23 Phase 3 Trial Planning Ongoing with FDA End - of - Phase 2 expected in mid - 2026 ATH434 - 201 Positive Topline Data ATH434 - 202 Positive Topline Data Data presentations and publications: x Annals of Clinical and Translational Neurology:
Slide 24: Alterity Therapeutics
ASX: ATH ofiys Alterity NASDAQ: ATHE THERAPEUTICS
Alterity Therapeutics — Shareholder Meeting (November 2025) on 6ix